Cell Medica is a cellular therapeutics company engaged in the development, manufacturing and marketing of cellular immunotherapy products for the treatment of cancer. Its lead oncology product, baltaleucel-T (CMD-003), is an autologous cell therapy in the CITADEL Phase 2 trial for Epstein‑Barr virus‑associated lymphomas and received FDA fast track designation in February 2017. The company develops products across three proprietary platforms: activated cytotoxic T cells, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs). Over the last year it expanded its technology base through strategic collaborations and the acquisition of Delenex Therapeutics, adding scFv generation and antibody‑secretion engineering capabilities. A partnership with Baylor College of Medicine focuses on CARs and NKT cell approaches to target solid tumours and explore an allogeneic off‑the‑shelf product, and a collaboration with UCL advances a Dominant TCR technology to improve TCR expression. Cell Medica will use the new funding to progress multiple cell‑based programmes, bring new products into Phase 1 trials and complete the Phase 2 programme for baltaleucel-T. Cell Medica is a London, UK-based cellular immunotherapy company focused on developing, manufacturing and marketing cellular immunotherapy products for cancer and infectious diseases. The company is advancing its lead oncology product, CMD-003, a patient-derived cell therapy being investigated in the CITADEL Phase 2 clinical trial for advanced Epstein–Barr virus–associated lymphomas. CMD-003 is comprised of the patient’s own immune cells and aims to provide a targeted cancer treatment with limited side effects or toxicities. Cell Medica is targeting a range of EBV-associated cancers including lymphoma, leukemia and nasopharyngeal carcinoma. Gregg Sando serves as Chief Executive Officer. The company intends to use new funding to further the development of its cellular immunotherapy products. Cell Medica is a London, UK-based clinical-stage cell therapeutics company that develops therapies based on the selection, activation and expansion of immune cells, specifically T-cells. Its Cytovir product family treats life-threatening viral infections in leukemia and lymphoma patients who have undergone bone marrow transplants. The company is targeting a European market launch of Cytovir CMV for cytomegalovirus infections in 2013 following completion of two randomized controlled studies underway in the UK. Led by CEO Gregg Sando and newly appointed Chairman Thomas Hecht, Cell Medica plans to expand its management team in both the US and Europe. The company intends to use new capital to continue development of its immune reconstitution cell therapies in Europe and to launch operations in Texas focused on cancer immunotherapy. Cell Medica is an early-stage cellular therapeutics company focused on developing cell-based treatments for infectious disease and cancer. Its lead work centers on Virus-specific Immune Reconstitution, a cell therapy technique to protect patients with weakened immune systems against cytomegalovirus (CMV) infections. The therapy is intended particularly for patients after bone marrow transplants. The company is commercialising this technique using proceeds from recent financing. Cell Medica raised £1.95m in the described funding round and has now raised a total of £4.5m in equity and convertible debt investment capital. The round was led by Imperial Innovations Group plc., with participation from private investors.

Total raised

$182M

Funding rounds

4

Latest round

Series C

Latest activity

Mar 2017